Warning: Last items in stock!
Availability date:
Mouse IGFBP-3 ELISA Kit
Recipient :
* Required fields
or Cancel
Assay Range | 156 - 10,000 pg/mL |
Sensitivity | 10.0 pg/mL |
Size | 96T |
Storage | Store at 2 - 8ºC. Keep reconstituted standard and detection Ab at -20 ºC |
Assay Principle | Sandwich ELISA |
Sample volume | 100 µL final volume, dilution factor varies on samples |
Detection Method | Chromogenic |
Kit Components
1. Recombinant Mouse IGFBP-3 standard: 2 vials
2. One 96-well plate precoated with anti- Mouse IGFBP-3 Ab
3. Sample diluent buffer: 12 mL - 1
4. Detection antibody: 130 µL, dilution 1:100
5. Streptavidin-HRP: 130 µL, dilution 1:100
6. Antibody diluent buffer: 12 mL x1
7. Streptavidin-HRP diluent buffer: 12 mL x1
8. TMB developing agent: 10 mL x1
9. Stop solution: 10 mL x1.
10. Washing solution (20x): 25 mL x1.
Background
Insulin-like growth factor-binding protein 3, also known as IGFBP3 or IBP-3, is encoded by the IGFBP3 gene in humans. IGFBP3 is a member of the insulin-like growth factor-binding protein (IGFBP) family. IGFBPs are cysteine-rich proteins with high binding affinity for IGF-I and IGF-II and play a key role in regulating IGF activity and availability in the circulation and extracellular environment. Human IGFBP-3, circulating in plasma, exists in a ternary complex with IGF-I or IGF-II and an acid-labile subunit (ALS) and affects the interaction of IGFs with their cell surface receptors. IGFBP-3 also exhibits IGF-independent anti-proliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R, suggesting that it may act as a negative regulator of tumorigenesis in certain carcinomas. The 264 amino acid (aa) mature mouse IGFBP-3 is derived from the 291 aa precursor by removing the 27 aa signal peptide. Mouse IGFBP-3 shares 93% and 81% aa sequence identity with rat and human IGFBP-3, respectively.
It is reported that serum levels of IGFBP 3 are decreased in AIDS, uncontrolled diabetes mellitus, trauma, and severe burns. Decreased levels of IGFBP 3 were also observed during the progression of prostate cancer.